Literature DB >> 17694962

An impedance-controlled system for endometrial ablation: five-year follow-up of 107 patients.

Adolf Gallinat1.   

Abstract

OBJECTIVE: To assess the safety, efficacy and data durability of the NovaSure endometrial ablation system 5 years after the procedure in women with severe menorrhagia secondary to dysfunctional uterine bleeding (DUB). STUDY
DESIGN: A prospective, single-arm, pilot study of 107 women undergoing endometrial ablation using the NovaSure system (Canadian Task Force classification II-1) at a specialized center for gynecologic endoscopy. The premenopausal women, with menorrhagia secondary to DUB unresponsive to medical therapy, had completed childbearing. A Pictorial Blood-Loss Assessment Chart was used to conduct a posttreatment evaluation of menstrual blood loss and bleeding pattern. Ablation was performed without any type of endometrial pretreatment.
RESULTS: No intraoperative or postoperative complications were observed. Treatment time averaged 94 seconds. At the 5-year follow-up, amenorrhea was reported by 75% of patients and successful reduction of bleeding was achieved in 98%, with hysterectomy and retreatment rates of 2.9% and 3.8%, respectively.
CONCLUSION: Long-term clinical results indicate that the NovaSure system is a safe and effective method for treatment of women with menorrhagia secondary to DUB. NovaSure yields high amenorrhea and success rates and low surgical reintervention rates 5 years after treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17694962

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  7 in total

Review 1.  Endometrial ablation for heavy menstrual bleeding.

Authors:  Vinod Kumar; Rohan Chodankar; Janesh Kumar Gupta
Journal:  Womens Health (Lond)       Date:  2016-01-12

Review 2.  Ambulatory management of heavy menstrual bleeding.

Authors:  Attilio Di Spiezio Sardo; Marialuigia Spinelli; Brunella Zizolfi; Carmine Nappi
Journal:  Womens Health (Lond)       Date:  2015-12-23

3.  Cost effectiveness of endometrial ablation with the NovaSure(®) system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and Medicaid payer perspectives.

Authors:  Jeffrey D Miller; Gregory M Lenhart; Machaon M Bonafede; Cindy M Basinski; Andrea S Lukes; Kathleen A Troeger
Journal:  Int J Womens Health       Date:  2015-01-06

4.  Cost-Effectiveness of Global Endometrial Ablation vs. Hysterectomy for Treatment of Abnormal Uterine Bleeding: US Commercial and Medicaid Payer Perspectives.

Authors:  Jeffrey D Miller; Gregory M Lenhart; Machaon M Bonafede; Andrea S Lukes; Shannon K Laughlin-Tommaso
Journal:  Popul Health Manag       Date:  2015-02-25       Impact factor: 2.459

5.  Clinical analysis of 2152 cases of abnormal uterine bleeding treated by NovaSure endometrial ablation.

Authors:  Hui Xie; Yajun Wan; Shuijing Yi; Fei Zeng; Xin Sun; Yimin Yang; Songshu Xiao
Journal:  Int J Gynaecol Obstet       Date:  2021-11-16       Impact factor: 4.447

6.  Does the radiofrequency impedance-controlled endometrial ablation have any morphologic effects on uterine leiomyomata? Report of 3 cases.

Authors:  Oluwole Fadare; Sa A Wang; Idris L Renshaw
Journal:  Diagn Pathol       Date:  2008-07-01       Impact factor: 2.644

Review 7.  Ten-year literature review of global endometrial ablation with the NovaSure® device.

Authors:  Richard J Gimpelson
Journal:  Int J Womens Health       Date:  2014-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.